Press release
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of Signatera in lung cancer.\n\n\nAn analysis of early-stage, resectable non-small cell lung cancer (NSCLC) patients will be featured in an oral presentation, demonstrating that Signatera status in the post-surgical molecular residual disease window is highly prognostic of recurrence-free survival and overall survival. Signatera Genome was used for this study, and the data highlights the potential of Signatera to individualize patient care by improving stratification of post-surgical recurrence risk.\n\n\n“Our data at WCLC reinforces the strong clinical utility of Signatera in lung cancer, which is the most common form of cancer diagnosed worldwide,” said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. “Notably, we look forward to sharing data on Signatera Genome that highlights its prognostic value for risk stratification in patients with early-stage, resectable NSCLC.”\n\n\nFull list of presentations at WCLC include:\n\n\nSeptember 7, 3:22 PM CEST | Presentation # MA03.02 (Oral Presentation)\nPresenter: Gaston Becharano, M.D.\nClinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC\n\n\nSeptember 8, 10:30 AM CEST | Presentation # P2.06.78\nPresenter: Daniel Rosas, M.D.\nUsing a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer\n\n\nSeptember 9, 10:00 AM CEST | Presentation # P3.18.04\nPresenter: Ken Masuda, M.D.\nMRDSEEKER (JCOG2111A): A Prospective Study to Evaluate MRD and Its Association With Prognosis in Curative-Intent NSCLC\n\n\nAbout Natera\nNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are sup...